Posts tagged ‘respiratory distress’

October 2013 newsletter

Lots of writing on this month’s PDF digest, much of it thanks to our registrars.  Rotavirus oral vaccination, wheezing in the under 2s, bradycardia, conduct disorder, Kawasaki disease and force feeding.  Do leave comments below.

January 2013 – Happy New Year!

I was a bit overloaded in December and couldn’t manage to get a newsletter out.  The nurses in my own ED noticed but I don’t think anyone else was particularly bothered!  Hope the Christmas break went well for everyone.  January 2013 brings some more on speech development, a reminder of the BTS 2008 guideline on cough, another plug for vitamin supplementation and part 2 of Jess Spedding’s minor injuries series.  Do leave comments below.

August 2012 PDF digest

August’s PDF only has 4 text boxes but with lots of information crammed into them and extra on the blog.  A great looking PDF on poisoning in children from one of our registrars, an article on stammering from another working with a speech and language therapist and an update on BTS pneumonia guidelines just in time for the winter.  Also a feature on Cardiff’s core info safeguarding work on the evidence behind different types of fractures.  Do leave comments…

BTS 2011 guideline on community acquired pneumonia in children

In October 2011 the British Thoracic Society updated its guidelines on community acquired pneumonia in children.  Dr Michael Eyres looked at it in more detail for Paediatric Pearls.  He was also part of our local audit team contributing to the national audit.  The results showed that we, despite insisting on as few investigations as possible, are still doing too many chest x-rays, blood cultures and CRP measurements.  Think – will it change management?

Here are the basics:

When to consider pneumonia

Persistent fever > 38.5°C     +     chest recessions    + tachypnoea

Investigations

• CXR should not be considered routine and is not required in children who do not need admission.

• Acute phase reactants including CRP are not useful in distinguishing viral from bacterial infection and should not
be tested routinely. Blood cultures also do not need to be routinely taken.

• Daily U&Es are required in children receiving IV fluids.

 

Severity assessment

• Children with oxygen saturations <92% need hospital referral.

• Auscultation findings of absent breath sounds with dullness to percussion need hospital referral.

• Children should be reassessed if symptoms persist.

 

General management

• Give parents information on managing fever, preventing dehydration and identifying deterioration.

• Children with oxygen saturations <92% need oxygen.

• NG tubes should be avoided in severe respiratory compromise and in infants.

• Chest physio is not beneficial and should not be performed in pneumonia.

 

Antibiotics

• All children with a clear clinical diagnosis of pneumonia should receive antibiotics as bacterial and viral
infections cannot be reliably distinguished. However most children younger than 2 years presenting with mild symptoms of respiratory distress (this would
include the bronchiolitics) do not usually require antibiotics.

• Amoxicillin is the oral first-line for all children as it is effective, well tolerated and cheap.

• Macrolides if no response to first-line / suspected mycoplasma or chlamydia / very severe disease.

• Augmentin if pneumonia associated with influenza.

• Oral agents are effective even in severe pneumonia; IV is needed only if unable to tolerate oral or there are
signs of septicaemia, empyema or abscess.

 

Follow-up

• Children with severe pneumonia or complications should be followed up after discharge until they have recovered completely and
CXR is near normal. Follow-up CXR is not otherwise required, but may be considered in round pneumonia, collapse or if symptoms persist.

 

 

Whooping cough outbreak 2012

More background to pertussis with thanks to Dr Rupa Vora

  • whooping cough is caused by Bordetella pertussis, a gram negative pleomorphic bacillus. It is spread by aerosol transmission and the bacteria cause damage by attaching to the respiratory cilia
  • it occurs in clusters every 2-5 years during the summer months. We currently have an outbreak with the HPA provisionally reporting 665 cases in the first quarter of 2012 (cf. 1040 cases in 2011, 421 in 2010)
  • cases have dropped dramatically since pertussis vaccinations have been introduced. Acellular pertussis vaccination is given at 2 and 3 months, followed by a pre-school booster.  However, protection wanes quickly and has virtually disappeared by 12 years old
  • incubation period is 3-12 days and children are most infectious in the first 2-3 weeks. They are most likely to present in the second phase of illness at 3-4 weeks
  • can present with coryza (1st stage which lasts a couple of weeks), paroxysms of cough, difficulty feeding and pneumonia. Younger infants (<6months) may not present with the characteristic ‘whoop’. Older children and adults often present with a persistent cough
  • complications include chronic cough (“100 day cough”), hypoglycaemia, seizures, encephalopathy and intracranial haemorrhage
  • any infant is vulnerable and up to 50% may need hospitalisation.  Especially vulnerable are ex-prems and those with underlying cardiology, respiratory or neurological problems.  
  • In England and Wales, whooping cough is statutorily notifiable.  The diagnosis is usually made on clinical grounds without the requirement for laboratory confirmation
  • The UK Health Protection Agency advises a 7 day course of erythromycin or clarithromycin (or azithromycin for 3-5 days if under 4 weeks) to reduce spread.  A pernasal swab to confirm or refute B. pertussis as the causative organism can be carried out.  If the cough has been present for more than two weeks and the child is in the community, serum serology can be sent to Colindale.  See table below:

 

Appropriate laboratory tests for a sporadic case of pertussis reported to HPA on clinical suspicion (with thanks to Dr Maria O’Callaghan): 

Age Clinical symptoms
≤ 2 weeks cough > 2 weeks cough
≤ 1 yr

Hospitalised

NPA/PNS for PCR (RSIL)

PNS for culture (local laboratory)

NPA/PNS for PCR (RSIL)

PNS for culture (local laboratory)

Serum for serology (RSIL)

≤ 1 yr

community

PNS for culture (local laboratory) Serum for serology (RSIL)
> 1 yr to 6 yr
6 to 15 yr Serum for serology (RSIL)
> 15 yr

 NPA – nasopharyngeal aspirate; PNS – pernasal swab;

RSIL – Respiratory and Systemic Infections Laboratory, Colindale

Useful websites:

HPA: www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/WhoopingCough/

NHS Choices: www.nhs.uk/Conditions/Whooping-cough/Pages/Introduction.aspx

Childhood Peak Expiratory Flow Rates (PEFR)

Children from about 5 years old may be able to use a Peak Flow Meter to record their PEFR. As one of the parameters by which we diagnose a severe or life-threatening asthma exacerbation is the percentage drop in PEFR, it would help to know what a child’s normal PEFR is! Click here for a guide of what you might expect for height. Children don’t always conform to these norms so it is important to know what the child’s own normal PEFR is; a 20% drop in their norm suggests poor control of asthma, a 40% drop suggests a significant exacerbation.

Inhalers for asthma

Most families in the Emergency Department will talk about their child’s “blue” and “brown” inhaler.  Can we, or they, tell which is the reliever and which the preventer? 

 Click here for a printable table of some common inhalers listed by colour.  I have also found a very useful site put together by a pharmacist and a medical student with photos of lots of the inhalers so you can get your patient to identify which one they are on.  Take a look at http://www.rch.org.au/clinicalguide/asthmadevices/

 Device   Comments
Standard metered dose inhaler (MDI)
  • Children < 12 years old unlikely to be able to use it properly without a spacer
  • Small, conveniently pocket-sized
  • Requires shaking and priming
  • Not affected by humidity
MDI and spacer
  • Bulky
  • Better delivery of drug at all ages
  • NICE suggests < 5 years, all inhalers should be given with a spacer device and 5-15 years, at least the corticosteroids should be given with a spacer
Dry powder device
  • Children < 6 years old generally can not use it as it requires a fast, deep breath to activate it
  • Medicine can be blown away if child accidentally breathes out
  • Clearer when the medicine is running out than the MDI
  • Single dose models require loading of capsules for each use
  • Powder sticks together if high humidity

 

http://www.asthma.org.uk/health_professionals/materials_to_help_you_your_patients/index.html has a link to a comprehensive information leaflet for young people over the age of 12 who need to take control of their asthma management and understand their condition.

http://www.nice.org.uk/nicemedia/live/11400/32073/32073.pdf  is the 2000 guideline on asthma management in the < 5 year olds

http://www.nice.org.uk/guidance/index.jsp?action=byID&r=true&o=11450 is the 2002 guideline for 5-15 year olds

Bronchiolitis season

 

With thanks to Amutha for this article….

As winter approaches, most of us are very well aware that the bronchiolitis season is in full swing. Bronchiolitis is a lower respiratory tract infection – in the under 1s predominantly – that can cause fever, dry cough, nasal discharge and bilateral fine inspiratory creps ± wheeze.  Most cases of bronchiolitis occur from November to March, when the viruses that can cause bronchiolitis are more common. It is also possible to get bronchiolitis more than once during the same winter season (1).

Treatment is largely supportive and many infants are managed at home if they are feeding adequately and do not have significant respiratory difficulty.  Patients at high risk are ex-premature babies, those with congenital cardiac or respiratory diseases, immunodeficiency and babies < 3months of age (2).  When seeing a child, we should focus our history and examination on risk factors, signs of dehydration and respiratory distress.  This podcast provides an example of respiratory distress:

 http://empem.org/2010/09/bronchiolitis-part-1-of-2/comment-page-1/#comment-294

 3% of children will present with severe illness and require admission (2).  Map of Medicine (http://healthguides.mapofmedicine.com/choices/map/bronchiolitis1.html)  defines “severe” as those with:

  • poor feeding – less than half normal intake
  • lethargy
  • history of apnoea
  • respiratory rate above 70breaths/minute
  • presence of nasal flare and/or grunting
  • severe chest wall recession
  • cyanosis
  • marked use of accessory muscles
  • marked intercostal and subcostal recession
  • oxygen saturation (SaO2) 94% or less

 There have been no therapies that have been consistently effective enough to change the current supportive management of bronchiolitis. The majority of trials show that bronchodilators do not provide benefit and their routine use is not recommended (3). 

 1.http://www.nhs.uk/conditions/Bronchiolitis/Pages/Introduction.aspx

 2. Scottish Intercollegiate Guidelines Network (SIGN). Bronchiolitis in children. A national clinical guideline. Edinburgh: SIGN; 2006. http://www.sign.ac.uk/pdf/sign91.pdf

3. Petruzella FDGorelick MH. Current therapies in bronchiolitis. Pediatr Emerg Care 2010 Apr;26(4):302-7